DISCLAIMER: This is an unofficial English translation of an original document in Spanish and is provided for information purposes only. In case of any discrepancy between this translation and the original Spanish text, the Spanish version shall prevail.

TO BME GROWTH

Barcelona, 14 March 2025

Pursuant to article 17 of Regulation (EU) 596/2014 of the European Parliament and of the Council of 16 April, on market abuse, and article 228 of the consolidated text of the Law on Market Securities and Investment Services, approved by Royal Legislative Decree 6/2023 of 17 March and its concordant provisions, as well as Circular 3/2020 of the BME Growth segment of BME MTF Equity, Holaluz-Clidom, S.A. ("**Holaluz**", the "**Firm**" or the "**Company**") hereby discloses the following

INSIDER INFORMATION

Following the disclosure of privileged information made by the Company to the market on 4 November 2024, Holaluz informs that, within the framework of ICOSIUM Investment, S.L. ("**ICOSIUM**") investment in the Company, in relation to the planned second phase, on 13 March 2025 the Company and ICOSIUM have signed a convertible loan for an amount of €15,519,999.60, at a conversion price of €2.10 per share (the "**Loan**").

The Loan is granted with the purpose of stabilising existing debt obligations with suppliers, strengthening the Company's cash position to finance daily working capital, and improving the Company's operational platform for natural gas and other green energies. The main characteristics of the Loan are as follows:

- **Total principal amount of the Loan:** €15,519,999.60.
- **Disbursement Date:** no later than 30 April 2025 (the "**Disbursement Date**").
- **Conversion Price:** The issue price of the ordinary shares to be issued upon conversion is €2.10 per share (the "**Conversion Price**"). The Conversion Price represents a premium of 52% compared to the closing price of Holaluz shares in the session immediately prior to the signing of the Loan.
- **Mandatory convertible nature:** the Loan is mandatorily convertible into newly issued ordinary shares of Holaluz of the same class and series and with identical rights as those currently in circulation at maturity. The number of shares to be issued for the purposes of converting the Loan into newly issued ordinary shares of the Company

will be determined by dividing the amounts owed by the Company under the Loan by the Conversion Price. If the number of shares is not a whole number, such number shall be rounded down to the nearest whole number of shares.

- **Maturity Date:** no later than 30 April 2025 (the "**Maturity Date**").

Furthermore, the founding shareholders of the Company have committed to ICOSIUM, simultaneously with the subscription of the Loan, to exercise all voting rights attributed to them in such capacity at the General Shareholders' Meeting in favour of a capital increase by offsetting credits and the delegation of its execution to the Board of Directors in accordance with article 297.1.a) of the Capital Companies Act; and in their capacity as directors, to hold a board meeting and vote in favour of the execution of said capital increase.

In compliance with the provisions of the BME MTF Equity Circular 3/2020, it is expressly stated that the information provided has been prepared under the exclusive responsibility of the Company and its directors.

Carlota Pi Amorós
coFounder and President
HOLALUZ-CLIDOM, S.A